Loading...
•
Mar 31
Lineage Q1 2025 Earnings Report
Lineage reported a narrower net loss for Q1 2025 despite a slight increase in revenue and stable expenses.
Key Takeaways
Lineage Cell Therapeutics posted a reduced net loss in Q1 2025 as operating expenses slightly declined and other income rose due to changes in warrant liabilities. The company continued progressing its clinical programs including OpRegen and OPC1.
Revenue for Q1 2025 was $1.5 million, driven mainly by collaboration revenue.
Net loss narrowed to $4.1 million from $6.5 million a year earlier.
Cash and cash equivalents reached $47.9 million, sufficient to support operations into Q1 2027.
Clinical studies advanced with key milestones including the launch of the OPC1 DOSED trial.
Lineage
Lineage
Lineage Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.comRoyalties & Licensing Revenue
CapyFin.com Forward Guidance
Lineage projects continued progress across clinical studies and expects its existing cash resources to fund operations into Q1 2027.
Positive Outlook
- OpRegen data continues to show durable treatment effect.
- 36-month update from Roche and Genentech expected in June.
- DOSED clinical study for OPC1 was initiated with UC San Diego as the first site.
- Continued collaboration support from Genentech.
- Strong cash position of $47.9 million extending runway into 2027.
Challenges Ahead
- Ongoing regional conflict in Israel may impact manufacturing.
- Dependency on third-party partnerships for clinical progression.
- Risk of insufficient manufacturing capabilities for clinical needs.
- Potential challenges in regulatory approval for OpRegen.
- Market competition from alternative therapies may limit commercial success.